EuBiologics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Public

  • Employees
  • 323


  • Stock Symbol
  • 206650

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $8.81
  • (As of Friday Closing)

EuBiologics General Information


EuBiologics Co Ltd is a biopharmaceutical company, which develops and supplies vaccines for epidemics and antibiotic resistance in South Korea. It offers Euvchol, an oral cholera prevention vaccine; and CRM197, a diphtheria toxin mutant vaccine, Inaba Cairo, and among others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Stock Exchange
Corporate Office
  • 8F, Seongdo Building, 207, Dosan-daero
  • Sinsa-dong, Gangnam-gu
  • Seoul
  • South Korea
+82 00-000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EuBiologics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.81 $8.79 $4.91 - $10.72 $321M 36.5M 315K -$0.29

EuBiologics Financials Summary

In Thousands,
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 324,466 324,466 254,549 1,052,525
Revenue 53,054 53,054 42,927 34,385
EBITDA (3,485) (3,485) 3,731 (20,756)
Net Income (10,615) (10,615) (850) (24,073)
Total Assets 117,799 117,799 128,327 126,416
Total Debt 11,468 11,468 12,402 13,043
Public Fundamental Data provided by Morningstar, Inc. disclaimer

EuBiologics Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore EuBiologics‘s full profile, request access.

Request a free trial

EuBiologics Patents

EuBiologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4212173-A1 Vaccine composition for chickenpox or varicella zoster and method of using same Pending 11-Sep-2020 000000000
US-20240033346-A1 Vaccine composition for chickenpox or varicella zoster and method of using same Pending 11-Sep-2020 000000000
EP-4026842-A1 Crm197 protein expression method Pending 03-Sep-2019 000000000
JP-2023139192-A Crm197 protein expression method Pending 03-Sep-2019 000000000
EP-4026842-A4 Crm197 protein expression method Pending 03-Sep-2019 C12N15/70 0
To view EuBiologics’s complete patent history, request access »

EuBiologics Executive Team (5)

Name Title Board Seat Contact Info
Yeong-ok Baek Ph.D Chief Executive Officer & Board Member
Young-shin Park Board Member & Executive
Choi Seuk-Keun Ph.D Chief Executive Officer
You’re viewing 3 of 5 executive team members. Get the full list »

EuBiologics Board Members (2)

Name Representing Role Since
Yeong-ok Baek Ph.D EuBiologics Chief Executive Officer & Board Member 000 0000
Young-shin Park EuBiologics Board Member & Executive 000 0000
To view EuBiologics’s complete board members history, request access »

EuBiologics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

EuBiologics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore EuBiologics‘s full profile, request access.

Request a free trial

EuBiologics Investments (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
LISCure Biosciences 25-Feb-2021 00000 0000 0000 Drug Discovery
POP Biotechnologies 16-Jul-2020 000000000 000 Drug Discovery
Premium Vaccine Devloper (Eubiologic /POP Biotech) 12-Jun-2020 00000 0000 Biotechnology
ATGC (Biotechnology) 01-Jan-2019 Later Stage VC 00.000 Biotechnology
To view EuBiologics’s complete investments history, request access »

EuBiologics ESG

Risk Overview

Risk Rating

Updated December, 24, 2022

44.04 | Severe Risk

Risk Scale

A lower score indicates better sustainability












Exposure refers to the extent to which a company is exposed to different material ESG issues



Management is related to actions taken to manage ESG issues


Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies

00 of 16,173






00 of 909






00 of 444




To view EuBiologics’s complete esg history, request access »

EuBiologics FAQs

  • When was EuBiologics founded?

    EuBiologics was founded in 2010.

  • Who is the CEO of EuBiologics?

    Yeong-ok Baek Ph.D and Choi Seuk-Keun Ph.D are the CEOs of EuBiologics.

  • Where is EuBiologics headquartered?

    EuBiologics is headquartered in Seoul, South Korea.

  • What is the size of EuBiologics?

    EuBiologics has 323 total employees.

  • What industry is EuBiologics in?

    EuBiologics’s primary industry is Drug Discovery.

  • Is EuBiologics a private or public company?

    EuBiologics is a Public company.

  • What is EuBiologics’s stock symbol?

    The ticker symbol for EuBiologics is 206650.

  • What is the current stock price of EuBiologics?

    As of 12-Apr-2024 the stock price of EuBiologics is $8.81.

  • What is the current market cap of EuBiologics?

    The current market capitalization of EuBiologics is $321M.

  • What is EuBiologics’s current revenue?

    The trailing twelve month revenue for EuBiologics is $53.1M.

  • What is EuBiologics’s annual earnings per share (EPS)?

    EuBiologics’s EPS for 12 months was -$0.29.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »